Ken Griffin Sellas Life Sciences Group, Inc. Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$0.84 - $1.35 $53,424 - $85,860	63,600 Added 39.07%	226,400 $228,000
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.39 $15,768 - $20,294	14,600 Added 9.85%	162,800 $203,000
Q2 2024 Aug 14, 2024	BUY	$1.06 - $1.63 $848 - $1,304	800 Added 0.54%	148,200 $176,000
Q1 2024 May 15, 2024	SELL	$0.51 - $1.55 $60,486 - $183,830	-118,600 Reduced 44.59%	147,400 $148,000
Q4 2023 Feb 14, 2024	BUY	$0.88 - $1.57 $9,768 - $17,427	11,100 Added 4.35%	266,000 $281,000
Q3 2023 Nov 14, 2023	SELL	$1.42 - $1.83 $28,116 - $36,234	-19,800 Reduced 7.21%	254,900 $418,000
Q2 2023 Aug 14, 2023	BUY	$1.35 - $1.8 $16,335 - $21,780	12,100 Added 4.61%	274,700 $431,000
Q1 2023 May 15, 2023	SELL	$1.18 - $3.86 $80,004 - $261,708	-67,800 Reduced 20.52%	262,600 $375,000
Q4 2022 Feb 14, 2023	SELL	$1.8 - $5.41 $85,680 - $257,516	-47,600 Reduced 12.59%	330,400 $779,000
Q3 2022 Nov 14, 2022	SELL	$2.02 - $3.38 $52,318 - $87,542	-25,900 Reduced 6.41%	378,000 $764,000

6.49M

1.8M

49.7K

Ticker SLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,551,900
Market Cap $24.7M
Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.